Seragen Biotherapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 22-06-2024
- Paid Up Capital ₹ 0.12 M
as on 22-06-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 116.06%
(FY 2020)
- Profit 1707.61%
(FY 2020)
- Ebitda 4676.74%
(FY 2020)
- Net Worth 1423.90%
(FY 2020)
- Total Assets 25.47%
(FY 2020)
About Seragen Biotherapeutics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Velmurugan Balasubramanian, Shrinivas Rangachari, and Vasanthi Palanivel serve as directors at the Company.
- CIN/LLPIN
U24304KA2018PTC114941
- Company No.
114941
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Seragen Biotherapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Velmurugan Balasubramanian  | Director | 20-Jul-2018 | Current |
| Shrinivas Rangachari | Director | 20-Jul-2018 | Current |
| Vasanthi Palanivel | Director | 01-Jun-2020 | Current |
Financial Performance and Corporate Structure Insights of Seragen Biotherapeutics.
Seragen Biotherapeutics Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 116.06% increase. The company also saw a substantial improvement in profitability, with a 1707.61% increase in profit. The company's net worth Soared by an impressive increase of 1423.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seragen Biotherapeutics?
Unlock access to Seragen Biotherapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Gensera Biotech Solutions Private Limited
Active 5 years 3 monthsVelmurugan Balasubramanian, Shrinivas Rangachari and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Seragen Biotherapeutics?
Unlock and access historical data on people associated with Seragen Biotherapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seragen Biotherapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seragen Biotherapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
